{{Rsnum
|rsid=1800584
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Orientation=minus
|Chromosome=6
|position=18130781
|Gene=TPMT
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|Gene_s=TPMT
}}{{CPMC SNP
|link=https://cpmc.coriell.org/Sections/Results/TPMT.aspx?pgId=221
}}

[[rs1800584]] is a rare SNP in the [[TPMT]] gene, potentially encoding a variant incapable of detoxifying byproducts of certain antineoplastic and immunosuppressant drugs. In general, individuals must have two nonfunctioning [[TPMT]] alleles for the toxicity to be pronounced.

The [[rs1800584]](A) SNP defines the TPMT*4A allele [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=187680&a=187680_AllelicVariant0003 (OMIM)].{{PMID|9486974|OA=1
}}

[[http://en.wikipedia.org/wiki/Thiopurine_methyltransferase| wikipedia]] thiopurine drugs metabolized by TPMT include [[azathioprine]], [[mercaptopurine]], and [[thioguanine]]

{{PharmGKB
|RSID=rs1800584
|Name_s=TPMT*4
|Gene_s=NHLRC1, TPMT
|Feature=Intron, Intron
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/tpmt/variant.jsp
|Annotation=This splicing variant results in very low TPMT activity and risk for hematologic toxicity as a result of treatment with thiopurines.
|Drugs=azathioprine; mercaptopurine
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA162359961
}}

{{ population diversity
| geno1 = (A;G)
| geno2 = (G;G)
| geno3 = 
| CEU | 1.8 | 98.2 | 0
| CHB | 0 | 0 | 0
| JPT | 0 | 0 | 0
| YRI | 0 | 0 | 0
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}